Combined injectable contraceptive
Combined Injectable Contraceptive
|First use||about 1980|
|Failure rates (first year)|
|Duration effect||1 month|
|Advantages and Disadvantages|
|Benefits||Especially good if poor pill compliance.|
Combined injectable contraceptive (CIC) monthly injection of progesterone and estradiol taken to inhibit fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle.
- October 5, 2000, Pharmacia received FDA approval for Lunelle™ Monthly Contraceptive Injection.
- April 2003, Pharmacia acquired by Pfizer (makers of Depo-provera).
- October 2003, Lunelle was discontinued in the U.S.
Use and packaging
The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.
- Lunelle contains medroxyprogesterone acetate (MPA) 25 mg plus estradiol cypionate (E2C) 5 mg.
- Cyclofem contains depomedroxy-progesterone acetate (DMPA) 25 mg and estradiol cypionate 5 mg.
- Mesigyna contains norethisterone enanthate (NET EN) 50 mg and estradiol valerate 5 mg.
- Deladroxate contains dihydroxy-progesterone acetophenide 150 mg and estradiol enanthate 10 mg.
- "FDA Approves Combined Monthly Injectable Contraceptive". Contraception Report. 12 (3). 2001.